J0666 HCPCS Level II code: Injection, bupivacaine liposome, 1 mg

J0666 is the HCPCS code for “Injection, bupivacaine liposome, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

J0666

Injection, bupivacaine liposome, 1 mg

Short description: Inj, bupivacaine liposome

HCPCS · United States

Medicare details

The indicators CMS publishes with J0666 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Carrier judgment
Medicare pricing
Drugs
ASC
Approved for ambulatory surgical centers
Type of service
Medical care
BETOS category
Other drugs
Added
Jan 1, 2025

Where J0666 sits

  1. 1J codesDrugs administered other than orally
  2. 2Active code J0666Injection, bupivacaine liposome, 1 mg

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code J0666 mean?

J0666 is the HCPCS code for “Injection, bupivacaine liposome, 1 mg” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover J0666?

CMS lists J0666’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.